CD8A and cancer: We observed that, compared to treatment with anti-PD-L1 alone, the combination of 2DG with anti-PD-L1 led to significant modulation of several pathways in CD8+ T cells, including immune response (PD1, PD-L1 cancer immunotherapy pathway) that is relevant to response to anti-PD-L1 treatment (Fig. 7a).